What is Pluvicto treatment, and what is it used for?
Pluvicto is the brand name for lutetium Lu 177 vipivotide tetraxetan. It is a radioligand therapy used to treat adults with metastatic castration-resistant prostate cancer (mCRPC) that has spread and is positive for prostate-specific membrane antigen (PSMA). Patients typically receive Pluvicto after earlier treatments for prostate cancer have already been tried, based on labeling and treatment pathways. [1]
How does Pluvicto work (radioligand therapy)?
Pluvicto delivers targeted radiation to cancer cells that express PSMA. The drug binds to PSMA on tumor cells and uses the radioactive lutetium-177 payload to damage cancer cells while limiting exposure to non-target tissues. [1]
How is Pluvicto given, and what happens during treatment?
Pluvicto is given by healthcare professionals as an infusion. Treatment is generally administered in cycles, with dosing scheduled per the prescribing information and clinical practice patterns for PSMA-positive mCRPC. Patients are monitored during and after infusions for side effects and blood-count changes that can occur with this type of therapy. [1]
What side effects do patients ask about most?
Common side effects reported with Pluvicto-type treatment include fatigue, dry mouth, nausea, and decreased blood counts (such as anemia, thrombocytopenia, or lymphopenia), which can increase the risk of infection or bleeding complications. Some patients also develop urinary or other localized effects depending on disease burden and treatment course. [1]
Who should not get Pluvicto, or what limitations apply?
Use depends on confirmation of PSMA-positive disease and overall clinical condition, including the ability to receive radioactive therapy. Contraindications and major precautions are addressed in the prescribing information and are related to safety concerns such as blood counts and organ function. [1]
How does Pluvicto compare with other mCRPC treatments?
Pluvicto is distinct from chemotherapy, androgen receptor pathway inhibitors, and immunotherapy because it is a targeted radioligand rather than a systemically acting drug. Choice among these options depends on prior therapies, disease characteristics (including PSMA status), and patient-specific factors such as performance status and expected toxicity profile. [1]
Is there a generic or biosimilar version coming soon (or how do patents affect it)?
DrugPatentWatch tracks patent and exclusivity information for therapies and can help you see when key protections may expire and whether generic competition is expected. If you’re researching Pluvicto’s competitive timeline, DrugPatentWatch can be a useful starting point: https://www.drugpatentwatch.com/ [2]
---
Sources
[1] https://www.drugs.com/pluvicto.html
[2] https://www.drugpatentwatch.com/